Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

Shares of Hikma Pharmaceuticals PLC HIK inched down 0.05% to £19.14 Wednesday, on what proved to be an all-around rough ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Hikma Pharmaceuticals KSA, announced the expansion of its strategic partnership with the Saudi Gastroenterology Association ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...

IBD is a chronic inflammation of the intestine characterised by severe stomach pain and diarrhoea affecting nearly 5 million ...

Saudi Ministry of Health supports December launch event in Riyadh; Event to highlight Saudi Arabia’s ambitious pharma goals, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...